Evidence map›Paper›PMID 27095597›Full record

ArticleJournal of proteomics2016

A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells.

Razan Sheta, Christina M Woo, Florence Roux-Dalvai, Frédéric Fournier, Sylvie Bourassa, Arnaud Droit, Carolyn R Bertozzi, Dimcho Bachvarov

Open access · greenAbstract read
In one paragraph

Article in Journal of proteomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. GalNAc-Transferases in Cancer.Biomedicines · 2025
    Review
  3. Article
  4. Article
  5. Mapping the cancer surface proteome in search of target antigens for immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Review
  6. Article
  7. Article
  8. Cell membrane-camouflaged liposomes for tumor cell-selective glycans engineering and imaging in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. GALNT6 suppresses progression of colorectal cancer.American journal of cancer research · 2018
    Article
  15. Ocoxin oral solutionOncology letters · 2017
    Article
  16. Chemical Glycoproteomics.Chemical reviews · 2016
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Razan ShetaDepartment of Molecular Medicine, Laval University, Québec, PQ, Canada; Centre de recherche du CHU de Québec, L'Hôtel-Dieu de Québec, Québec, PQ, Canada.
Christina M WooDepartment of Chemistry, Stanford University, Stanford, CA, USA.
Florence Roux-DalvaiCentre de recherche du CHU de Québec, CHUL, Québec, PQ, Canada.
Frédéric FournierCentre de recherche du CHU de Québec, CHUL, Québec, PQ, Canada.
Sylvie BourassaCentre de recherche du CHU de Québec, CHUL, Québec, PQ, Canada.
Arnaud DroitDepartment of Molecular Medicine, Laval University, Québec, PQ, Canada; Centre de recherche du CHU de Québec, CHUL, Québec, PQ, Canada.
Carolyn R BertozziDepartment of Chemistry, Stanford University, Stanford, CA, USA; Howard Hughes Medical Institute, Stanford University, Stanford, CA, USA.
Dimcho BachvarovDepartment of Molecular Medicine, Laval University, Québec, PQ, Canada; Centre de recherche du CHU de Québec, L'Hôtel-Dieu de Québec, Québec, PQ, Canada.
Stanford University · USUniversité Laval · CAHôtel-Dieu de Québec · CA

Funding

Investigating the Surface GlycoproteomeR01CA200423 · NCI · STANFORD UNIVERSITY · PI Carolyn Bertozzi · 2015 to 2026
$3.8M
Howard Hughes Medical InstituteNCI NIH HHS R01 CA200423
6 · The paper itself

Abstract

unlabelledEpithelial ovarian cancer (EOC) is a disease responsible for more deaths among women in the Western world than all other gynecologic malignancies. There is urgent need for new therapeutic targets and a better understanding of EOC initiation and progression. We have previously identified the polypeptide N-acetylgalactosaminyltransferase 3 (GALNT3) gene, a member of the GalNAc-transferases (GalNAc-Ts) gene family, as hypomethylated and overexpressed in high-grade serous EOC tumors, compared to low malignant potential EOC tumors and normal ovarian tissues. This data also suggested for a role of GALNT3 in aberrant EOC glycosylation, possibly implicated in disease progression. To evaluate differential glycosylation in EOC caused by modulations in GALNT3 expression, we used a metabolic labeling strategy for enrichment and mass spectrometry-based characterization of glycoproteins following GALNT3 gene knockdown (KD) in A2780s EOC cells. A total of 589 differentially expressed glycoproteins were identified upon GALNT3 KD. Most identified proteins were involved in mechanisms of cellular metabolic functions, post-translational modifications, and some have been reported to be implicated in EOC etiology. The GALNT3-dependent glycoproteins identified by this metabolic labeling approach support the oncogenic role of GALNT3 in EOC dissemination and may be pursued as novel EOC biomarkers and/or therapeutic targets. BIOLOGICAL SIGNIFICANCE: Knowledge of the O-glycoproteome has been relatively elusive, and the functions of the individual polypeptide GalNAc-Ts have been poorly characterized. Alterations in GalNAc-Ts expression were shown to provide huge variability in the O-glycoproteome in various pathologies, including cancer. The application of a chemical biology approach for the metabolic labeling and subsequent characterization of O-glycoproteins in EOC using the Ac4GalNAz metabolite has provided a strategy allowing for proteomic discovery of GalNAc-Ts specific functions. Our study supports an essential role of one of the GalNAc-Ts - GALNT3, in EOC dissemination, including its implication in modulating PTMs and EOC metabolism. Our approach validates the use of the applied metabolic strategy to identify important functions of GalNAc-Ts in normal and pathological conditions.

Indexed as

Gene Expression ProfilingFemaleGene Knockdown TechniquesGlycoproteinsGlycosylationHumansN-AcetylgalactosaminyltransferasesOvarian NeoplasmsPolypeptide N-acetylgalactosaminyltransferaseProteomicsGlycoproteinsN-AcetylgalactosaminyltransferasesPolypeptide N-acetylgalactosaminyltransferaseEpithelial ovarian cancerGALNT3GlycoproteomicsGlycosylationMetabolic labelingPathway and network analysis

Identifiers

PMID27095597
PMCPMC5436706
OpenAlexW2339875460

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.